Pfizer Establishes Durham, North Carolina, Clinical Manufacturing Campus
12/23/2021
According to company officials, the facility will be responsible for the manufacturing and analytical release of clinical supplies for Pfizer’s gene therapy and biologics portfolio. Approximately 40 employees will relocate from the company’s Chapel Hill site.
The Durham facility is part of an $800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy research, development, and manufacturing.
“Gene therapy represents the next wave of innovation for patients living with rare diseases, for whom there are limited treatment options currently available,” said Paul Mensah, Vice President, BioTherapeutics Pharmaceutical Sciences at Pfizer. “Today represents the next step in strengthening Pfizer’s in-house gene therapy capabilities and underscores the unique ability, expertise, and resources we have to guide gene therapy through the entire development and manufacturing process and deliver this potentially life-changing technology to patients.”
Pfizer currently employs more than 3,600 people across its North Carolina sites, according to company officials. The new Durham location is an important part of Pfizer’s worldwide R&D network which includes locations in La Jolla, California; Boulder, Colorado; St Louis, Missouri; Pearl River, New York; Groton, Connecticut; and Cambridge and Andover, Massachusetts.
Project Announcements
Anduril Industries Plans Long Beach-Lakewood, California, Operations
02/08/2026
Dongwon Autopart Technology Plans Emanuel County, Georgia, Production Operations
02/07/2026
Quantum Machines Plans Chicago, Illinois, Operations
02/06/2026
Utilidata Expands Ann Arbor, Michigan, Operations
02/05/2026
Wilbur Products-MOTIV Bowling Expands Roosevelt Park, Michigan, Operations
02/05/2026
InnovAsian Cuisine Enterprises Plans Jonesboro, Arkansas, Production Operations
02/04/2026
Most Read
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
The New Industrial Revolution in Biotech
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025